Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

A specific and antagonistic technology, applied in the field of pancreatic adenoma, saliva, and adenoma, can solve the problems of little understanding of the role and narrowing the scope of surgery

Inactive Publication Date: 2010-02-10
GENENTECH INC
View PDF49 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second, the reduction in tumor volume allows for a smaller surgical field thus preserving the patient's organ and its function
[0014] Despite evidence suggesting a role for VEGF in the development of disorders or diseases involving pathological angiogenesis, including advanced and metastatic or disseminated The role of tumors, malignancies, or secondary sites of micrometastases in the development of tumors is poorly understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
  • Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
  • Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0333] Example 1. Inhibition of VEGF-A leads to arrest of intestinal adenoma growth and Apc min / + Long-term survival of mice

[0334] The syndrome of familial adenomatous polyposis (FAP) and most sporadic colorectal cancers are caused by mutations in the APC gene. FAP patients develop hundreds to thousands of adenomatous polyps in their lower gastrointestinal (GI) tract, in addition to extracolonic tumors including desmoids and tumors of the upper GI tract. Apc with heterozygous truncated allele at codon 850 min / + Mice mimic some of the features of polyposis in FAP patients with germline APC mutations (Moser et al., Science 247:322-324 (1990), Su et al., Science 256:668-670 (1992)). Apc min / + The onset of tumor formation in mice is early adulthood and animals typically develop 60-150 intestinal polyps on the C57BL / 6 genetic background. Tumor development results in severely impaired lifespan in mice, usually leading to death around five months of age due to anemia and / or bl...

Embodiment 2

[0394] Example 2. Anti-VEGF-A monoclonal antibody inhibits pituitary adenoma growth and reduces serum prolactin and growth hormone levels in a mouse model of multiple endocrine neoplasia

[0395] Multiple endocrine neoplasia (MEN) is a condition characterized by tumors involving two or more endocrine glands. Patients were classified as MEN type 1 (MEN1) when a co-occurrence of tumors in the parathyroid glands, islet cells, and anterior pituitary was identified. Mutations in the MEN1 gene, which generally lead to truncation or deficiency of the protein menin, were found to cause the disorder (reviewed in Pannett et al., Endocr. Relat. Cancer 6:449-473 (1999)). With more discoveries about frequent deletions of the remaining alleles in tumors (Bystrom et al., Proc. Natl. Acad. Sci USA 87: 1968-1972 (1990), Debelenko et al., Cancer Res. 57: 2238- 2243 (1997), Larsson et al., Nature 332:85-87 (1988)), MEN1 has been classified as a tumor suppressor gene. Although MEN1 is largely i...

Embodiment 3

[0442] Example 3. Anti-VEGF Intervention Efficacy and Regression / Survival Efficacy in the RIP-TβAg Model of Multistage Carcinogenesis

[0443] To better understand the role of anti-VEGF therapy at different stages of tumor growth, we turned to a number of preclinical tumor models, including RIP-TβAg. RIP-TβAg (Exelixis, Inc.) is produced (driven) by transgenic expression of the SV40 large T antigen (TAg), which targets pancreatic beta cells, where TAg acts as a potent oncogene by binding p53 and Rb A conditional format of the mouse islet tumor model. RIP-T[beta]Ag is phenotypically similar to previously described RIP-TAg models (Hanahan, Nature 315: 115-122 (1985); Bergers et al., Science 284(808-811), 1999). We have found that this model develops through a series of increasingly aggressive periods, including the activation of VEGF signaling and the "angiogenic switch" (ie, the initiation of the process of forming new blood vessels) at approximately 5 weeks. Small tumors for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

Disclosed herein are methods of treating benign, pre-cancerous, or non- metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developingbenign, pre-cancerous, or non- metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.

Description

Background of the invention [0001] Cancer is one of the deadliest threats to human health. In the United States alone, cancer strikes nearly 1.3 million new patients each year and is the second leading cause of death after cardiovascular disease, accounting for approximately 1 in 4 deaths. Solid tumors are responsible for most of these deaths. Despite remarkable advances in the medical treatment of certain cancers, the overall 5-year survival rate for all cancers has only improved by about 10% over the past 20 years. Cancer or malignant tumors metastasize and grow rapidly in an uncontrolled manner, making timely detection and treatment very difficult. [0002] Current approaches to cancer treatment are relatively non-selective and typically target tumors after the cancer has progressed to a more aggressive stage. Surgery removes diseased tissue; radiation therapy shrinks solid tumors; and chemotherapy rapidly kills dividing cells. Chemotherapy in particular causes a number...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K38/19A61K38/43A61K39/395A61P35/00
Inventor 纳波利昂·费雷拉尼娜·克斯萨里罗伯特·D·麦斯
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com